Fintel reports that on February 5, 2025, Jefferies upgraded their outlook for Cardinal Health (NYSE:CAH) from Hold to Buy.

Jefferies has upgraded Cardinal Health (CAH) to buy from hold, citing management's emerging EPS track record. Read more here.

Shares of Cardinal Health Inc. CAH advanced 1.82% to $127.45 Wednesday, on what proved to be an all-around great trading ...

Cardinal Health reported an increase in revenue for two of its segments, while the departure of Optimum impacted its ...

Cardinal Health warned Thursday that if President Donald Trump follows through with threatened tariffs next month, higher prices for some of the company's products will follow. Trump is set to ...

Jefferies analyst Brian Tanquilut upgraded Cardinal Health (CAH) to Buy from Hold with a price target of $150, up from $140. The firm thinks ...

Cardinal Health (NYSE:CAH – Free Report) had its target price upped by Morgan Stanley from $136.00 to $142.00 in a research ...

Bank of America Securities analyst Allen Lutz maintained a Buy rating on Cardinal Health (CAH – Research Report) today. The company’s shares ...

Dublin City Schools is officially withdrawing from an agreement with Cardinal Health to purchase a vacant office building, Superintendent John Marschhausen told board members at a meeting Monday ...

Second quarter revenue for Cardinal Health's global medical products and distribution segment increased 1% to $3.2 billion, driven by volume growth from existing customers. The company’s global ...

Jan 30 (Reuters) - Drug distributor Cardinal Health on Thursday raised its fiscal ... attracted by the lucrative profit potential of these products. Earlier this month, Cardinal said it expects ...